Moderate-to-Vigorous Exercise Lowers Preterm Birth Risk With Gestational Diabetes
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
MONDAY, Dec. 23, 2024 -- Moderate- to vigorous-intensity physical activity (MVPA) during pregnancy is inversely associated with preterm birth in women with gestational diabetes (GD), according to a study published online Dec. 19 in JAMA Network Open.
Wanglong Gou, Ph.D., from Westlake Laboratory of Life Sciences and Biomedicine in China, and colleagues examined the association of accelerometer-derived physical activity metrics and patterns with preterm birth among women with GD. The analysis included 1,427 women with GD with wearable accelerometer-derived physical activity data.
The researchers found an inverse relationship between an increase in MVPA and the fraction of physical activity energy expenditure derived from MVPA with preterm birth (odds ratio per 30 minutes, 0.64 and 0.69, respectively). There was a progressive decrease in the odds of preterm birth with increasing duration of MVPA per day, which reached a plateau at 74 minutes per day. The benefit was similar whether active MVPA (≥30 minutes per day) was concentrated into a few days or followed a more regular pattern.
"These findings provide key evidence for the health benefits of MVPA during pregnancy and lay the foundation for establishing physical activity guidelines for pregnant women with GD," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-24 12:00
Read more
- Study Looks at Impact of Children's Exposure to Lead in the United States
- Colon Cancer Rates Are Up Among the Young Worldwide
- 2019 to 2022 Saw Increase in E-Scooter/Bike-Related Injury ED Visits
- 2013 to 2022 Saw Increase in Influenza Testing at Hospital ED Visits
- SABCS: Omission of Axillary Staging Noninferior for Node-Negative Breast Cancer
- Scientists Spot Gene That Could Help Cause Miscarriages
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions